SOPH

SOPH

USD

SOPHiA GENETICS SA Ordinary Shares

$3.160+0.060 (1.935%)

Precio en Tiempo Real

Healthcare
Health Information Services
Suiza

Gráfico de Precios

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$3.100

Máximo

$3.200

Mínimo

$3.050

Volumen

0.00M

Fundamentos de la Empresa

Capitalización de Mercado

211.2M

Industria

Health Information Services

País

Switzerland

Estadísticas de Negociación

Volumen Promedio

0.06M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $2.58Actual $3.160Máximo $6.28

Informe de Análisis de IA

Última actualización: 22 abr 2025
Generado por IAFuente de Datos: Yahoo Finance, Bloomberg, SEC

SOPH: SOPHiA GENETICS SA Ordinary Shares - Analyzing Recent Moves & What Might Come Next

Stock Symbol: SOPH Generate Date: 2025-04-22 20:48:14

Alright, let's break down what's been happening with SOPHiA GENETICS stock (SOPH) based on the latest info. We'll look at the news, the price chart, and what the AI model is predicting.

Recent News Buzz: What's the Vibe?

The main piece of news hitting the wires recently, specifically on April 8th, was about SOPHiA GENETICS teaming up with Precision for Medicine. This partnership is all about expanding services for biopharma companies, specifically using SOPHiA's DDM platform and its capabilities for analyzing liquid biopsies.

Think of it this way: SOPHiA has this cool software platform that helps analyze complex genetic data. Precision for Medicine helps drug companies develop and sell their products. By partnering, Precision for Medicine can now offer SOPHiA's advanced analysis tools to their drug company clients, especially for things like liquid biopsies (which are less invasive than traditional tissue biopsies).

The vibe from this news is definitely positive. It shows SOPHiA's technology is valuable enough for another player in the healthcare space to build services around it. It's a good sign for their platform's adoption and potential revenue down the line.

Price Check: What's the Stock Been Doing?

Looking at the price history over the last few months, it's been a bit of a rollercoaster, but the overall trend has been downwards since a peak in mid-February. The stock hit highs around $4.88 back then but has since drifted lower, recently touching lows around $2.58 in early April.

The current price is sitting around $2.91. So, it's bounced a little off those recent lows but is still significantly down from its earlier highs. The trading volume has been pretty inconsistent, sometimes seeing spikes (like in late January/mid-February and early March/late March), but often quite low, which is typical for smaller companies like this one.

Now, let's factor in the AI's short-term look ahead. The AI predicts a very slight dip today (-0.14%), but then sees positive movement for the next two days (+2.64% and +1.97%). This suggests the AI thinks the recent downward pressure might be easing, and there could be a small bounce coming up.

Putting It Together: Outlook & Strategy Ideas

Based on the positive news about the partnership, the stock price being near its recent lows, and the AI predicting a potential short-term upward move, the apparent near-term leaning here seems to be cautiously positive, perhaps leaning towards a 'hold' or a 'potential buy' for those comfortable with the risks.

Here's the thinking: The news is fundamentally good – it expands SOPHiA's reach and validates their technology. The price has been beaten down, which could mean it's undervalued if the company can execute on these partnerships and improve its financials over time. The AI's prediction of a bounce adds a short-term technical signal to consider.

Potential Entry Consideration: If you were thinking about this stock, the current price area, or perhaps a dip back towards the recent low or the AI's suggested support level around $2.73 or $2.82, might be areas to watch. The idea here is potentially getting in near a recent bottom if you believe the positive news and AI prediction signal a turning point. But remember, prices can always go lower.

Potential Exit/Stop-Loss Consideration: Managing risk is key. If you were to consider an entry, setting a stop-loss below a recent low, like the AI's suggested $2.50, could be a way to limit potential losses if the price continues to fall instead of bouncing. For potential upside, the AI suggests a take-profit level around $3.29. These are just potential guideposts based on the data provided.

Company Context

It's important to remember that SOPHiA GENETICS is a healthcare tech company focused on analyzing complex data using its software platform. The partnership news fits perfectly into their core business of working with biopharma companies. This isn't a huge company; it has a relatively small market capitalization and can have low trading volume, which often means the stock price can be quite volatile and move sharply on news or even small trading volumes. Also, the company's financials, like its negative P/E and ROE, and higher debt levels, are fundamental challenges to keep in mind despite the positive operational news and technical signals.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock investing involves significant risk, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Noticias Relacionadas

PR Newswire

SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion ...

Ver más
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
PR Newswire

Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities

Precision for Medicine, a leading provider of drug development and commercialization services, today announced a strategic partnership with SOPHiA...

Ver más
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities
PR Newswire

Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities

Precision for Medicine, a leading provider of drug development and commercialization services, today announced a strategic partnership with SOPHiA...

Ver más
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities

Predicción de IABeta

Recomendación de IA

Alcista

Actualizado el: 28 abr 2025, 12:23

BajistaNeutralAlcista

62.2% Confianza

Riesgo y Negociación

Nivel de Riesgo4/5
Riesgo Alto
Adecuado Para
Valor
Guía de Negociación

Punto de Entrada

$3.09

Toma de Ganancias

$3.31

Stop Loss

$2.79

Factores Clave

PDI 33.7 está por encima de MDI 31.3 con ADX 14.9, lo que sugiere una tendencia alcista
El volumen de operaciones es 3.9 veces el promedio (1,560), lo que indica una presión de compra extremadamente fuerte
El MACD 0.0355 está por debajo de la línea de señal 0.0362, lo que indica un cruce bajista

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.